Eisai reports positive data from Phase Ib/II study of lenvatinib for RCC

Eisai has reported positive interim results from a Phase Ib/II clinical trial (Study 111) of Kisplyx (lenvatinib) in combination with Merck ’s anti-PD-1 therapy pembrolizumab (Keytruda) to treat patients with advanced renal cell carcinoma (RCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news